Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Status
Conditions
Treatments
Details and patient eligibility
About
In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery. Specifically, investigators examined the impact of targeted therapy or immune check point inhibitors (ICIs) in combination with preoperative chemotherapy on (1) prognostic differences based on initial progression (invading adjacent organs) and metastatic site (peritoneum, distant lymph node [LN]) at the time of stage IV gastric cancer diagnosis and (2) conversion surgery outcomes and pathological complete response (pCR).
Enrollment
Sex
Volunteers
Inclusion criteria
- Stage IV gastric cancer patients who underwent conversion surgery
Exclusion criteria
- Patients who did not undergo gastrectomy
- Patients who underwent emergent surgery due to cancer perforation
- Patients with missing medical records or information
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal